Lewis K, Maio M, Demidov L, et al. BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma. ESMO 2017, abstract LBA7_PR.
OLVG start met immunotherapie voor long- en niercelkanker
jul 2017 | Longoncologie, Uro-oncologie